Immunotherapy for Ovarian Cancer: Disappointing or Promising?

Mol Pharm. 2024 Feb 5;21(2):454-466. doi: 10.1021/acs.molpharmaceut.3c00986. Epub 2024 Jan 17.


Ovarian cancer, one of the deadliest malignancies, lacks effective treatment, despite advancements in surgical techniques and chemotherapy. Thus, new therapeutic approaches are imperative to improving treatment outcomes. Immunotherapy, which has demonstrated considerable success in managing various cancers, has already found its place in clinical practice. This review aims to provide an overview of ovarian tumor immunotherapy, including its basics, key strategies, and clinical research data supporting its potential. In particular, this discussion highlights promising strategies such as checkpoint inhibitors, vaccines, and pericyte transfer, both individually and in combination. However, the advancement of new immunotherapies necessitates large controlled randomized trials, which will undoubtedly shape the future of ovarian cancer treatment.

Keywords: CAR-T therapy; checkpoint blockers; immunotherapy; ovarian cancer; vaccines.

Publication types

  • Review

MeSH terms

  • Cancer Vaccines* / therapeutic use
  • Female
  • Humans
  • Immunotherapy / methods
  • Ovarian Neoplasms* / drug therapy
  • Treatment Outcome


  • Cancer Vaccines